☆ 4.3 Letter

Late relapse of primary central nervous system lymphoma

LEUKEMIA & LYMPHOMA (2017)

Journal

LEUKEMIA & LYMPHOMA

Volume 58, Issue 2, Pages 475-477

Publisher

TAYLOR & FRANCIS LTD

DOI: 10.1080/10428194.2016.1201570

Keywords

-

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

Relapsed Primary Central Nervous System Lymphoma: Current Advances

Kaiyan Tao, Xuefeng Wang, Xin Tian

Summary: Primary Central Nervous System Lymphoma (PCNSL) relapses are often derived from occult lymphoma cells, with treatment options including chemotherapy, radiation therapy, stem cell transplantation, targeted therapy, and immunotherapy. The overall prognosis is very poor, with early and varied clinical symptoms.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Hematology

Advances in treatment of elderly primary central nervous system lymphoma

Nicolas Martinez-Calle, Lisa K. Isbell, Kate Cwynarski, Elisabeth Schorb

Summary: Managing primary central nervous system lymphoma in older individuals is a clinical challenge. Optimal therapy and adequate dose intensity are key issues, with high-dose methotrexate-based immunochemotherapy still being the recommended induction treatment. Utilizing geriatric assessment tools and considering individual performance status and comorbidities are important in personalized treatment approaches.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Review Oncology

Current and emerging therapies for primary central nervous system lymphoma

Yan Yuan, Tianling Ding, Shu Wang, Hong Chen, Ying Mao, Tong Chen

Summary: PCNSL is a rare type of lymphoma primarily treated with high-dose methotrexate-based chemotherapy, stem cell transplantation, and whole-brain radiotherapy. Future treatments may focus on targeted therapy and personalized medicine.

BIOMARKER RESEARCH (2021)

Add to Collection

Review Oncology

Challenges in the management of primary central nervous system lymphoma

Xuefei Sun, Liwei Lv, Yuchen Wu, Qu Cui, Shengjun Sun, Nan Ji, Yuanbo Liu

Summary: Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma. Stereotactic biopsy is the gold standard for diagnosis, but new auxiliary diagnostic methods such as cytokines and tumor circulating DNA show promise. Consolidation treatments, such as whole brain radiotherapy, autologous hematopoietic stem cell transplantation, and non-myeloablative chemotherapy, are being emphasized but there is uncertainty about the optimal strategy. This article reviews the diagnosis and treatment of PCNSL, focusing on research progress in consolidation therapy.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

Add to Collection

Review Hematology

Primary central nervous system lymphoma

Lauren R. Schaff, Christian Grommes

Summary: Primary central nervous system lymphoma (PCNSL) is a rare malignancy that affects the brain, spinal cord, or eye. Early diagnosis and timely treatment are crucial for optimal outcomes. Advances in high-dose methotrexate chemotherapy have improved prognosis, but relapse is still common. Novel treatments targeting abnormal pathways show promise for relapsed/refractory PCNSL.

BLOOD (2022)

Add to Collection

Review Oncology

Prognostic models in primary central nervous system lymphoma patients: A systematic review

Jelena Jelicic, Thomas Stauffer Larsen, Zoran Bukumiric, Karen Juul-Jensen, Bosko Andjelic

Summary: Various prognostic models have been proposed for PCNSL in the past decade, but consensus on the optimal model is still lacking. Age and performance status are important prognostic factors, but due to limitations such as small patient numbers and lack of validation, a universally accepted model has not been established. Future multicentre studies are needed to determine the optimal prognostic model for PCNSL.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection

Article Immunology

Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma

Zhiguang Lin, Jingjing Ma, Yan Ma, Qing Li, Hui Kang, Mengxue Zhang, Bobin Chen, Rong Xia

Summary: Circulating NK cells have a prognostic impact on primary central nervous system lymphoma (PCNSL). Patients with higher counts and proportions of NK cells have better prognosis, and the changes in NK cell counts before and after chemotherapy are also associated with prognosis. Higher NK cell counts are associated with longer overall survival, while higher fold changes in NK cell proportions and counts are associated with longer progression-free survival.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Genetics & Heredity

Molecular characteristics of immunocytes infiltration in primary central nervous system lymphoma

Linyun Zhang, Fei Sun, Xiaona Lu, Xiaotong Wang, Jie Wang, Jun Li, Yingsong Xu, Daqing Kou, Hongtao Lv, Bin Don

Summary: The tumor microenvironment in PCNSL is closely associated with tumor immune response. Higher ICI scores in PCNSL patients are correlated with a better tumor microenvironment, sensitivity to immunotherapy, and certain small molecule drugs. This study identified genes associated with ICI scores that may serve as important therapeutic and prognostic targets for PCNSL.

FRONTIERS IN GENETICS (2022)

Add to Collection

Review Cell Biology

Understanding the molecular pathogenesis of primary central nervous system lymphoma by experimental animal models

Di Wu, Dahai Liu, Kensuke Tateishi, Fei Qi, Fang Yang, Chao Ke, Hua You

Summary: This review article presents the phenotypic and genotypic features of primary central nervous system lymphoma (PCNSL) tumor cells, and compiles the preclinical animal models of PCNSL. Researchers hope that these animal models will enhance the understanding of the molecular pathogenesis of PCNSL and accelerate the development of novel therapeutic strategies.

JOURNAL OF CELLULAR PHYSIOLOGY (2023)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

High 18F-FDOPA PET Uptake in Primary Central Nervous System Lymphoma

Betty Salgues, Elsa Kaphan, Elicia Molines, Gilles Brun, Eric Guedj

Summary: The study presented a 42-year-old female patient with primary central nervous system lymphoma (PCNSL) and strong uptake on F-18-FDOPA PET, similar to previous findings with C-11-MET PET. Therefore, PCNSL should be considered as a possible differential neoplastic diagnosis in cases of F-18-FDOPA uptake.

CLINICAL NUCLEAR MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Analysis of genomic alterations in primary central nervous system lymphoma

Xin He, Xiaotong Fan, Yongzhi Shan, Xinrui Ji, Lan Su, Yaming Wang

Summary: In this study, next-generation sequencing was used to investigate the genomic profile of primary central nervous system lymphoma (PCNSL). The most common mutation type and mutated genes in PCNSL were identified. Enrichment analysis revealed the involvement of mutated genes in various pathways and functional protein activities. This study provides insights into the molecular mechanisms of PCNSL and potential targets for diagnosis and precision medicine.

MEDICINE (2023)

Add to Collection

Review Oncology

Evidence-based expert consensus on the management of primary central nervous system lymphoma in China

Tong Chen, Yuanbo Liu, Yang Wang, Qing Chang, Jinsong Wu, Zhiliang Wang, Daoying Geng, Jin-Tai Yu, Yuan Li, Xiao-Qiu Li, Hong Chen, Dongxiao Zhuang, Jianyong Li, Bin Wang, Tao Jiang, Lanting Lyu, Yuqin Song, Xiaoguang Qiu, Wenbin Li, Song Lin, Xinghu Zhang, Dehong Lu, Junqiang Lei, Yaolong Chen, Ying Mao

Summary: This consensus provides specific and evidence-based recommendations for the histopathological diagnosis, imaging examinations, treatment regimens, and management of complications in PCNSL patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Health Care Sciences & Services

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy

Isabel Cornell, Ayisha Al Busaidi, Stephen Wastling, Mustafa Anjari, Kate Cwynarski, Christopher P. Fox, Nicolas Martinez-Calle, Edward Poynton, John Maynard, Steffi C. Thust

Summary: By studying the changes in tumour volume and apparent diffusion coefficient (ADC) measurements in PCNSL patients treated with MATRix chemotherapy, we found that ADC and T1CE metrics are potential biomarkers for predicting treatment response. Response after four cycles of chemotherapy differed from response after two cycles. Baseline ADC and T1CE metrics were predictive of MATRix treatment response. Standard interim response assessment (after two cycles) did not reliably predict early disease progression.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Primary Central Nervous System Lymphoma: Clinical Evaluation of Automated Segmentation on MultiparametricMRIUsing Deep Learning

Lenhard Pennig, Ulrike Cornelia Isabel Hoyer, Lukas Goertz, Rahil Shahzad, Thorsten Persigehl, Frank Thiele, Michael Perkuhn, Maximilian Ruge, Christoph Kabbasch, Jan Borggrefe, Liliana Caldeira, Kai Roman Laukamp

Summary: This study investigated the performance of a deep-learning model in automatically detecting and segmenting primary central nervous system lymphoma on clinical MRI. The results showed that the automated segmentations had good spatial overlap with manual segmentations for total tumor volume and tumor core, and the performance was comparable between initial and follow-up scans.

JOURNAL OF MAGNETIC RESONANCE IMAGING (2021)

Add to Collection

Review Oncology

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma

Ruben Van Dijck, Jeanette K. Doorduijn, Jacoline E. C. Bromberg

Summary: Primary central nervous system lymphoma (PCNSL) is a rare type of cancer limited to the central nervous system, with poor prognosis. The use of high-dose methotrexate-based chemotherapy is agreed upon for newly diagnosed patients, but the addition of rituximab for improving survival remains disputed. The available evidence of rituximab's effectiveness in PCNSL is still uncertain.

CANCERS (2021)

Add to Collection

Article Oncology

So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?

Masayuki Kanamori, Hirokazu Takami, Shigeru Yamaguchi, Takashi Sasayama, Koji Yoshimoto, Teiji Tominaga, Akihiro Inoue, Naokado Ikeda, Atsushi Kambe, Toshihiro Kumabe, Masahide Matsuda, Shota Tanaka, Manabu Natsumeda, Ken-Ichiro Matsuda, Masahiro Nonaka, Jun Kurihara, Masayoshi Yamaoka, Naoki Kagawa, Naoki Shinojima, Tetsuya Negoto, Yukiko Nakahara, Yoshiki Arakawa, Seiji Hatazaki, Hiroaki Shimizu, Atsuo Yoshino, Hiroshi Abe, Jiro Akimoto, Yu Kawanishi, Tomonari Suzuki, Atsushi Natsume, Motoo Nagane, Yukinori Akiyama, Dai Keino, Tadateru Fukami, Takahiro Tomita, Kohei Kanaya, Tsutomu Tokuyama, Shuichi Izumoto, Mitsutoshi Nakada, Daisuke Kuga, Shohei Yamamoto, Ryogo Anei, Takeo Uzuka, Junya Fukai, Noriyuki Kijima, Keita Terashima, Koichi Ichimura, Ryo Nishikawa

Summary: In this study, a multicenter retrospective analysis was conducted to investigate cases with specific criteria related to germ cell tumors (GCTs). The results showed that all patients meeting the criteria had GCTs or granulomatous inflammation, not other types of tumors. Biopsy was recommended, considering the presence of non-germinomatous GCTs in at least 3.4% of the patients and the safety and efficacy of simultaneous procedures for acute hydrocephalus.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Clinical Neurology

GLI3 Is Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma

Manabu Natsumeda, Hiroaki Miyahara, Junichi Yoshimura, Satoshi Nakata, Takanori Nozawa, Junko Ito, Yu Kanemaru, Jun Watanabe, Yoshihiro Tsukamoto, Masayasu Okada, Makoto Oishi, Junko Hirato, Takafumi Wataya, Sama Ahsan, Kensuke Tateishi, Tetsuya Yamamoto, Fausto J. Rodriguez, Hitoshi Takahashi, Volker Hovestadt, Mario L. Suva, Michael D. Taylor, Charles G. Eberhart, Yukihiko Fujii, Akiyoshi Kakita

Summary: The study shows that GLI3 is highly expressed in both WNT-activated and SHH-activated medulloblastoma, with GLI1 and GLI3 being highly expressed in SHH-activated medulloblastoma. In contrast, GLI3 is significantly expressed in WNT-activated medulloblastoma while GLI1 is suppressed.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2021)

Add to Collection

Article Oncology

Topoisomerase IIβ immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group

Hiroaki Miyahara, Manabu Natsumeda, Yonehiro Kanemura, Kai Yamasaki, Yuichi Riku, Akio Akagi, Wataru Oohashi, Tomoko Shofuda, Ema Yoshioka, Yuya Sato, Takashi Taga, Yuki Naruke, Ryo Ando, Daiichiro Hasegawa, Makiko Yoshida, Tsukasa Sakaida, Naoki Okada, Hiroyoshi Watanabe, Michio Ozeki, Yoshiki Arakawa, Junichi Yoshimura, Yukihiko Fujii, Souichi Suenobu, Kenji Ihara, Junichi Hara, Akiyoshi Kakita, Mari Yoshida, Yasushi Iwasaki

Summary: The study highlights the association of GLI3, NM, GFAP, and TOP2 beta expressions with prognosis in medulloblastomas, showing different clinical characteristics and outcomes among NM-/GFAP-, NM+/GFAP-, and GFAP+ subgroups.

BRAIN TUMOR PATHOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Low Detection Rate of H3K27M Mutations in Cerebrospinal Fluid Obtained from Lumbar Puncture in Newly Diagnosed Diffuse Midline Gliomas

Jotaro On, Manabu Natsumeda, Jun Watanabe, Shoji Saito, Yu Kanemaru, Hideaki Abe, Yoshihiro Tsukamoto, Masayasu Okada, Makoto Oishi, Junichi Yoshimura, Akiyoshi Kakita, Yukihiko Fujii

Summary: Recent studies have shown the feasibility of detecting H3K27M mutations in diffuse midline glioma patients' cerebrospinal fluid. However, liquid biopsy only achieved a definitive detection of the mutation in a small percentage of patients. Younger age and higher concentration of CSF protein tended to be associated with cases where a definitive assessment was possible.

DIAGNOSTICS (2021)

Add to Collection

Article Clinical Neurology

Endovascular treatment of an infectious aneurysm using the selective provocative test and transcranial motor evoked potential monitoring under general anesthesia: a case report

Kazuhiro Ando, Tetsuya Hiraishi, Makoto Oishi, Hitoshi Hasegawa, Bumpei Kikuchi, Manabu Natsumeda, Tomoaki Suzuki, Shoji Saito, Tomoyoshi Ota, Yuichi Yoshida, Yukihiko Fujii

Summary: The use of SPT under general anesthesia with transcranial MEP monitoring is safe and effective for patients with ruptured fusiform aneurysms in the middle cerebral artery M4 segment.

ACTA NEUROCHIRURGICA (2022)

Add to Collection

Article Oncology

Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features

Manabu Natsumeda, Michael Chang, Ramil Gabdulkhaev, Haruhiko Takahashi, Yoshihiro Tsukamoto, Yu Kanemaru, Masayasu Okada, Makoto Oishi, Kouichirou Okamoto, Fausto J. Rodriguez, Akiyoshi Kakita, Yukihiko Fujii, Karisa C. Schreck

Summary: Detecting BRAF V600E mutation in GBMs is crucial due to potential treatment implications, however, the scarcity of these mutations poses challenges for molecular testing in all GBMs. Analyzing clinical, radiographic, and pathologic features of BRAF V600E-mutant GBM compared to controls revealed specific MRI characteristics, higher likelihood of total resection, and distinctive epithelioid features, emphasizing the importance of testing for BRAF V600E in IDH-wildtype GBM.

BRAIN TUMOR PATHOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma

Yasuo Takashima, Atsushi Kawaguchi, Junya Fukai, Yasuo Iwadate, Koji Kajiwara, Hiroaki Hondoh, Ryuya Yamanaka

Summary: Dysregulation of cell morphology and cell-cell interaction is crucial for cancer cell growth and metastasis. The balance between ECM and MMP plays a key role in cancer cell morphology and angiogenesis. Gene signatures associated with PCNSL morphology and microenvironment were identified through NGS, with prognostic prediction formulas developed and collagen genes found to contribute to microenvironment regulation. A combinatorial expression of representative genes enabled precise prognosis prediction and diagnosis of PCNSL cell types with MTX resistance.

PLOS ONE (2021)

Add to Collection

Article Medicine, General & Internal

Less-invasive diagnosis of disseminated epithelioid glioblastoma harboring BRAF V600E mutation by cerebrospinal fluid analysis-A case report

Manabu Natsumeda, Yu Kanemaru, Yukie Kawaguchi, Hajime Umezu, Akiyoshi Kakita, Yukihiko Fujii

Summary: Spinal dissemination in epithelioid glioblastoma can be diagnosed by detecting BRAF V600E mutation in cerebrospinal fluid cytology and liquid biopsy.

CLINICAL CASE REPORTS (2021)

Add to Collection

Article Clinical Neurology

Four-dimensional multifusion imaging for assessment of meningioma hemodynamics

Ryosuke Ogura, Makoto Oishi, Tetsuya Hiraishi, Haruhiko Takahashi, Kohei Shibuya, Tomoaki Suzuki, Manabu Natsumeda, Kouichirou Okamoto, Yukihiko Fujii

Summary: The new method of 4-dimensional (4D)-multifusion imaging integrates hemodynamic information to analyze arterial feeders, tumor stain patterns, and drainage routes in meningiomas. Dynamic images simulate blood flow and can be used for pre-surgical simulation and treatment planning.

INTERDISCIPLINARY NEUROSURGERY-ADVANCED TECHNIQUES AND CASE MANAGEMENT (2021)

Add to Collection

Article Oncology

Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study

Tomokazu Aoki, Naoki Kagawa, Kazuhiko Sugiyama, Toshihiko Wakabayashi, Yoshiki Arakawa, Shigeru Yamaguchi, Shota Tanaka, Eiichi Ishikawa, Yoshihiro Muragaki, Motoo Nagane, Mitsutoshi Nakada, Satoshi Suehiro, Nobuhiro Hata, Junichiro Kuroda, Yoshitaka Narita, Yukihiko Sonoda, Yasuo Iwadate, Manabu Natsumeda, Yoichi Nakazato, Hironobu Minami, Yuki Hirata, Shunsuke Hagihara, Ryo Nishikawa

Summary: The study assessed the efficacy and safety of nivolumab in Japanese patients with first recurrence glioblastoma, achieving the prespecified efficacy criterion of 1-year overall survival and demonstrating a good safety profile.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide

Takeyoshi Eda, Masayasu Okada, Ryosuke Ogura, Yoshihiro Tsukamoto, Yu Kanemaru, Jun Watanabe, Jotaro On, Hiroshi Aoki, Makoto Oishi, Nobuyuki Takei, Yukihiko Fujii, Manabu Natsumeda

Summary: This study found that clindamycin has cytotoxic effects on glioblastoma cells and its mechanism of action involves the inhibition of the mTOR pathway and the suppression of MGMT protein expression. The combination of clindamycin and temozolomide shows promising synergistic antitumor activity.

CANCERS (2022)

Add to Collection

Article Medicine, General & Internal

Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of False-Positive Cases

Manabu Natsumeda, Hironaka Igarashi, Ramil Gabdulkhaev, Haruhiko Takahashi, Kunio Motohashi, Ryosuke Ogura, Jun Watanabe, Yoshihiro Tsukamoto, Kouichirou Okamoto, Akiyoshi Kakita, Tsutomu Nakada, Yukihiko Fujii

Summary: The study re-evaluated five glioma cases for IDH2 mutations, identifying rare mutations in two cases. MRS demonstrated higher specificity for detecting IDH1/2 mutations than originally reported.

DIAGNOSTICS (2021)

Add to Collection

Article Medicine, General & Internal

Successful Treatment of Acute Uric Acid Nephropathy with Rasburicase in a Primary Central Nervous System Lymphoma Patient Showing a Dramatic Response to Methotrexate-Case Report

Yoshihiro Mouri, Manabu Natsumeda, Noritaka Okubo, Taro Sato, Taiki Saito, Kohei Shibuya, Shiori Yamada, Jotaro On, Yoshihiro Tsukamoto, Masayasu Okada, Makoto Oishi, Takeyoshi Eda, Junko Murai, Hiroshi Shimizu, Akiyoshi Kakita, Yukihiko Fujii

Summary: This study reports a case of a PCNSL patient who developed acute renal failure and hyperuricemia after MTX treatment. By using rasburicase rescue, the patient's renal function was restored and controlled.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Oncology

Reciprocal expression of the immune response genes CXCR3 and IFI44L as module hubs are associated with patient survivals in primary central nervous system lymphoma

Yasuo Takashima, Momoko Hamano, Kengo Yoshii, Azusa Hayano, Junya Fukai, Yasuo Iwadate, Koji Kajiwara, Hiroaki Hondoh, Ryuya Yamanaka

Summary: The study investigated expression modules reflecting the reciprocal expression of cancer microenvironment and immune response-related genes associated with poor prognosis in primary central nervous system lymphoma (PCNSL). Weighted gene coexpression network analysis revealed representative modules including neurogenesis, immune response, anti-virus, microenvironment, gene expression, and translation, extracellular matrix, morphogenesis, and cell adhesion. The results suggest that the differential expression and balance of immune response and microenvironment genes may play a crucial role in the growth and prognosis prediction of PCNSL tumors.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Prognosis prediction with cancer immunity microRNAs in PCNSL

Yasuo Takashima, Atsushi Kawaguchi, Yasuo Iwadate, Hiroaki Hondoh, Junya Fukai, Koji Kajiwara, Azusa Hayano, Ryuya Yamanaka

CANCER SCIENCE (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.